Results 171 to 180 of about 39,492 (194)

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study

Journal of Clinical Oncology, 2020
Steven P Fling, Nirasha Ramchurren, Martin A Cheever   +2 more
exaly  

Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal

Journal of Clinical Oncology, 2010
Julia Scarisbrick
exaly  

The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients

British Journal of Dermatology, 2019
Julia Scarisbrick, Hm Prince, Rudi Stadler   +2 more
exaly  

TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)

Blood, 2007
Youn H Kim, Sean Whittaker, Reinhard Dummer   +2 more
exaly  

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model

Journal of Clinical Oncology, 2015
Henry M Prince, Maarten H Vermeer, Pietro Quaglino   +2 more
exaly  

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

European Journal of Cancer, 2006
Robert Knobler, Reinhard Dummer
exaly  

MYCOSIS FUNGOIDES

AJN, American Journal of Nursing, 1961
openaire   +1 more source

Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk‐stratification, and management

American Journal of Hematology, 2019
Alexandra C Hristov, Trilokraj Tejasvi, Ryan A Wilcox   +2 more
exaly  

Mycosis fungoides

1985
openaire   +2 more sources

Mycosis fungoides.

The British journal of dermatology and syphilis, 2010
openaire   +5 more sources